Caldwell Sutter Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caldwell Sutter Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23	Closed	-$1.25K	–	880
2025 Q3	$1.25K	Hold	23	–	–	﹤0.01%	785
2025 Q2	$1.26K	Hold	23	–	–	﹤0.01%	760
2025 Q1	$1.63K	Hold	23	–	–	﹤0.01%	748
2024 Q4	$1.51K	Sell	23 -8	-26%	-$536	﹤0.01%	778
2024 Q3	$2.18K	Hold	31	–	–	﹤0.01%	746
2024 Q2	$2.55K	Hold	31	–	–	﹤0.01%	726
2024 Q1	$2.71K	Hold	31	–	–	﹤0.01%	713
2023 Q4	$2.99K	Hold	31	–	–	﹤0.01%	700
2023 Q3	$2.74K	Hold	31	–	–	﹤0.01%	687
2023 Q2	$2.69K	Buy	31 +23	+288%	+$2.16K	﹤0.01%	694
2023 Q1	$778	Buy	+8	New	+$829	﹤0.01%	538

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caldwell Sutter Capital's BMRN Position: Q4 2025 in Review

Caldwell Sutter Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 23 shares — an estimated $1.25K sold.

Caldwell Sutter Capital first reported a position in BMRN in Q1 2023 and held it in 11 quarters. The position peaked at $2.99K in Q4 2023. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Caldwell Sutter Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Caldwell Sutter Capital sold 23 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.25K.
Caldwell Sutter Capital first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 11 quarters.
Caldwell Sutter Capital's BioMarin Pharmaceuticals position peaked at $2.99K in Q4 2023.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Caldwell Sutter Capital's 13F filing for Q4 2025, filed 30 Jan 2026.